{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:31:55Z","timestamp":1780047115962,"version":"3.53.1"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002918","name":"Gentofte Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"University of Copenhagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.peptides.2024.171214","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:03:43Z","timestamp":1712901823000},"page":"171214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety of native glucose-dependent insulinotropic polypeptide in humans"],"prefix":"10.1016","volume":"177","author":[{"given":"Mads M.","family":"Helsted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina L.","family":"Schaltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e6rke S.","family":"Gasbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel B.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2024.171214_bib1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/nu13030883","article-title":"Nutrient-induced cellular mechanisms of gut hormone secretion","volume":"13","author":"Lu","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.peptides.2024.171214_bib2","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1210\/jcem-25-10-1317","article-title":"Intestinal factors in the control of insulin secretion","volume":"25","author":"McIntyre","year":"1965","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0014-5793(84)81114-X","article-title":"The isolation and sequencing of human gastric inhibitory peptide (GIP)","volume":"172","author":"Moody","year":"1984","journal-title":"FEBS Lett."},{"key":"10.1016\/j.peptides.2024.171214_bib8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diabetes.53.3.654","article-title":"Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib9","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1210\/jc.2013-3809","article-title":"Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease","volume":"99","author":"Idorn","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib10","first-page":"3575","article-title":"Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide 1","volume":"85","author":"Deacon","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molmet.2016.04.007","article-title":"Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets","volume":"5","author":"DiGruccio","year":"2016","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib12","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00125-003-1103-y","article-title":"Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia","volume":"46","author":"Meier","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170194","article-title":"The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system","volume":"125","author":"Adriaenssens","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2024.171214_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170174","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease","volume":"125","author":"Heimb\u00fcrger","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2024.171214_bib18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2337\/db11-1451","article-title":"Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes","volume":"61","author":"Wice","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib19","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0196-9781(00)00287-4","article-title":"Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells","volume":"21","author":"Zhong","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2024.171214_bib20","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/EC-17-0015","article-title":"Effects of meal and incretins in the regulation of splanchnic blood flow","volume":"6","author":"Koffert","year":"2017","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.peptides.2024.171214_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jc.2015-3133","article-title":"Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDITION-PRO study","volume":"101","author":"M\u00f8ller","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib23","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid Re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib24","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2016-1933","article-title":"Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans","volume":"101","author":"Asmar","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib25","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1530\/EC-19-0144","article-title":"GIP-induced vasodilation in human adipose tissue involves capillary recruitment","volume":"8","author":"Asmar","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.peptides.2024.171214_bib26","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/clinchem\/45.10.1858","article-title":"Diurnal rhythm of crosslaps in human serum","volume":"45","author":"Wichers","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.peptides.2024.171214_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S8756-3282(01)00662-7","article-title":"Mechanism of circadian variation in bone resorption","volume":"30","author":"Bjarnason","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.peptides.2024.171214_bib28","doi-asserted-by":"crossref","first-page":"E2325","DOI":"10.1210\/jc.2014-2547","article-title":"Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans","volume":"99","author":"Nissen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1210\/jc.2017-01949","article-title":"Glucose-Dependent Insulinotropic Polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia","volume":"103","author":"Christensen","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib30","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1210\/jc.2019-00008","article-title":"Separate and combined effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes","volume":"104","author":"Bergmann","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115079","article-title":"GIP\u2019s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3\u201330)NH2","volume":"130","author":"Gasbjerg","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.peptides.2024.171214_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib33","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.","volume":"91","author":"Nauck","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2024.171214_bib35","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.","volume":"101","author":"Flint","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2024.171214_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.peptides.2024.171214_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.peptides.2024.171214_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with Type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib43","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2024.171214_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.peptides.2024.171214_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2024.171214_bib46","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bph.13323","article-title":"Species-specific action of (Pro3)GIP - A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors","volume":"173","author":"Sparre-Ulrich","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2024.171214_bib48","first-page":"1095","article-title":"Fasting and postprandial GIP values in pigs, rats, dogs, and man measured with five different GIP antisera","volume":"19","author":"Amland","year":"1984","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.peptides.2024.171214_bib49","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jcem-69-3-654","article-title":"Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8","volume":"69","author":"Nauck","year":"1989","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib50","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man. 1","volume":"37","author":"Dupre","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib51","first-page":"912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.","volume":"76","author":"Nauck","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib52","doi-asserted-by":"crossref","first-page":"E621","DOI":"10.1152\/ajpendo.00499.2003","article-title":"Gastric inhibitory polypeptide does not inhibit gastric emptying in humans","volume":"286","author":"Meier","year":"2004","journal-title":"Am. J. Physiol. -Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/dom.12395","article-title":"Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors","volume":"17","author":"Aaboe","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib54","series-title":"Identification and Actions of Gastric Inhibitory Polypeptide, in: Proc. 1974 Laurent. Horm. Conf","first-page":"487","author":"Brown","year":"1975"},{"key":"10.1016\/j.peptides.2024.171214_bib55","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/oby.2008.229","article-title":"GLP-1 (9-36) Amide, Cleavage Product of GLP-1 (7-36) Amide, Is a Glucoregulatory Peptide","volume":"16","author":"Elahi","year":"2008","journal-title":"Obesity"},{"key":"10.1016\/j.peptides.2024.171214_bib56","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"330","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2024.171214_bib57","doi-asserted-by":"crossref","first-page":"E949","DOI":"10.1152\/ajpendo.1995.268.5.E949","article-title":"Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8","volume":"268","author":"Fieseler","year":"1995","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib58","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1172\/JCI1349","article-title":"Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.","volume":"101","author":"Schirra","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2024.171214_bib59","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/diabetes.50.11.2497","article-title":"Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes","volume":"50","author":"Meier","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib60","first-page":"2015","article-title":"Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction 1","volume":"86","author":"Kindmark","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib61","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1210\/jc.2003-030738","article-title":"The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide\u2014regardless of etiology and phenotype","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","article-title":"Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects","volume":"114","author":"Vilsb\u00f8ll","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2024.171214_bib63","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/diabetes.53.9.2359","article-title":"Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients","volume":"53","author":"Rudovich","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib64","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1210\/jc.2005-0382","article-title":"Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight","volume":"90","author":"Schou","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib65","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.3748\/wjg.v12.i12.1874","article-title":"Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls","volume":"12","author":"Meier","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.peptides.2024.171214_bib66","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2007.07.002","article-title":"The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance","volume":"144","author":"Knop","year":"2007","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2024.171214_bib67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1210\/jc.2008-1731","article-title":"Channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"94","author":"Aaboe","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib68","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2337\/db08-0958","article-title":"Exogenous glucose\u2013dependent insulinotropic polypeptide worsens post prandial hyperglycemia in t ype 2 diabetes","volume":"58","author":"Chia","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2265.2008.03451.x","article-title":"Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes","volume":"71","author":"Daousi","year":"2009","journal-title":"Clin. Endocrinol. (Oxf. )"},{"key":"10.1016\/j.peptides.2024.171214_bib70","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1152\/ajpendo.00639.2009","article-title":"On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans","volume":"298","author":"Asmar","year":"2010","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib71","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1365-2982.2010.01554.x","article-title":"Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis: incretins, gastric emptying and metabolic control","volume":"22","author":"Edholm","year":"2010","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.peptides.2024.171214_bib72","doi-asserted-by":"crossref","first-page":"E1038","DOI":"10.1152\/ajpendo.00665.2010","article-title":"The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes","volume":"300","author":"Lund","year":"2011","journal-title":"Am. J. Physiol. -Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib73","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/db10-1332","article-title":"GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes","volume":"60","author":"Mentis","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.regpep.2012.08.004","article-title":"In vivo effect of glucose-dependent insulinotropic peptide (GIP) on the gene expression of calcitonin peptides in human subcutaneous adipose tissue","volume":"179","author":"Pivovarova","year":"2012","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2024.171214_bib75","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.2337\/dc13-0307","article-title":"The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically Ill","volume":"36","author":"Lee","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2024.171214_bib76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ijo.2013.73","article-title":"Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects","volume":"38","author":"Asmar","year":"2014","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2024.171214_bib77","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1210\/jc.2013-3994","article-title":"GIP contributes to islet trihormonal abnormalities in type 2 diabetes","volume":"99","author":"Chia","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib78","doi-asserted-by":"crossref","first-page":"E418","DOI":"10.1210\/jc.2013-3644","article-title":"Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes","volume":"99","author":"Christensen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13054-014-0718-3","article-title":"Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study","volume":"19","author":"Kar","year":"2015","journal-title":"Crit. Care"},{"key":"10.1016\/j.peptides.2024.171214_bib80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s00125-015-3522-y","article-title":"Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance","volume":"58","author":"Eriksen","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib81","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1152\/ajpendo.00520.2014","article-title":"Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics","volume":"308","author":"Karstoft","year":"2015","journal-title":"Am. J. Physiol. -Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib82","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.2337\/dc14-1452","article-title":"Effect of exogenous intravenous administrations of GLP-1 and\/or GIP on circulating pro-atrial natriuretic peptide in subjects with different stages of glucose tolerance","volume":"38","author":"Rudovich","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2024.171214_bib83","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00125-015-3618-4","article-title":"GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial","volume":"58","author":"G\u00f6gebakan","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2016.15","article-title":"The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss","volume":"6","author":"Asmar","year":"2016","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib85","doi-asserted-by":"crossref","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","article-title":"Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response","volume":"312","author":"Thondam","year":"2017","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib86","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00125-017-4447-4","article-title":"GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study","volume":"61","author":"Gasbjerg","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib87","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","article-title":"Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: a randomised, crossover study","volume":"62","author":"Bergmann","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib88","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1210\/clinem\/dgz048","article-title":"Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease","volume":"105","author":"J\u00f8rgensen","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib89","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2337\/db20-0074","article-title":"GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1\u03b1 mutation carriers","volume":"69","author":"Christensen","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib90","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/dc19-0578","article-title":"No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon-like peptide 1 receptor agonist in men with type 2 diabetes","volume":"43","author":"Bergmann","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2024.171214_bib91","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/dom.14186","article-title":"Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide ( GIP) receptor antagonist GIP (3-30) NH 2 on GIP actions in humans","volume":"23","author":"Gasbjerg","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib92","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2337\/db14-0440","article-title":"Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes","volume":"64","author":"Christensen","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib93","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.2337\/db22-0399","article-title":"Effects of GLP-1 and GIP on islet function in glucose-intolerant, pancreatic-insufficient cystic fibrosis","volume":"71","author":"Nyirjesy","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib94","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ejendo\/lvac015","article-title":"The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans","volume":"188","author":"Krogh","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.peptides.2024.171214_bib95","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"Role of gastrointestinal hormones in postprandial reduction of bone resorption: gastrointestinal hormones and reduction of bone resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.peptides.2024.171214_bib96","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0026-0495(03)00327-5","article-title":"Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects","volume":"52","author":"Meier","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.peptides.2024.171214_bib97","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.2337\/diabetes.53.suppl_3.S220","article-title":"Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib98","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bone.2019.05.014","article-title":"GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men","volume":"125","author":"Skov-Jeppesen","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.peptides.2024.171214_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116065","article-title":"Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: a preliminary study","volume":"152","author":"Skov-Jeppesen","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.peptides.2024.171214_bib100","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/jbmr.4308","article-title":"The antiresorptive effect of gip, but not gLP -2, is preserved in patients with hypoparathyroidism\u2014a randomized crossover","volume":"36","author":"Skov-Jeppesen","year":"2021","journal-title":"Study, J. Bone Miner. Res."},{"key":"10.1016\/j.peptides.2024.171214_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106058","article-title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment","volume":"176","author":"Gabe","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.peptides.2024.171214_bib102","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00125-021-05547-8","article-title":"The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial","volume":"64","author":"Heimb\u00fcrger","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171214_bib103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2337\/db14-0440","article-title":"Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes","volume":"64","author":"Christensen","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib104","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1210\/jc.2008-1731","article-title":"KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"94","author":"Aaboe","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib105","first-page":"dgac542","article-title":"GIP affects hepatic fat and brown adipose tissue thermogenesis, but not white adipose tissue transcriptome in T1D","author":"Heimb\u00fcrger","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib106","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.121.17852","article-title":"Worsening postural tachycardia syndrome is associated with increased glucose-dependent insulinotropic polypeptide secretion","volume":"79","author":"Breier","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2024.171214_bib107","doi-asserted-by":"crossref","unstructured":"F.K. Knop, S. Urva, M. Rettiganti, C.T. Benson, W.C. Roell, K.J. Mather, A. Haupt, E.J. Pratt, Abstract 648 of the 59thEASD Annual Meeting of the European Association for the Study of Diabetes, Diabetologia 66 (2023) 1\u2013536. https:\/\/doi.org\/10.1007\/s00125-023-05969-6.","DOI":"10.1007\/s00125-023-05969-6"},{"key":"10.1016\/j.peptides.2024.171214_bib108","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2337\/dbi21-0004","article-title":"The role of GIP in the regulation of GLP-1 satiety and nausea","volume":"70","author":"Hayes","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib109","article-title":"Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation","volume":"55","author":"Costa","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib110","doi-asserted-by":"crossref","DOI":"10.2337\/db23-56-OR","article-title":"56-OR: a long-acting glucose-dependent insulinotropic polypeptide receptor agonist shows weight loss without nausea or vomiting","volume":"72","author":"Knop","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2024.171214_bib111","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.cell.2012.02.010","article-title":"Diabetes mellitus and the \u03b2 cell: the last ten years","volume":"148","author":"Ashcroft","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.peptides.2024.171214_bib112","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41580-020-00317-7","article-title":"Mechanisms controlling pancreatic islet cell function in insulin secretion","volume":"22","author":"Campbell","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.peptides.2024.171214_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115553","article-title":"The role of endogenous GIP and GLP-1 in postprandial bone homeostasis","volume":"140","author":"Helsted","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.peptides.2024.171214_bib114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/EJE-21-0135","article-title":"Effects of endogenous GIP in patients with type 2 diabetes","volume":"185","author":"Stensen","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.peptides.2024.171214_bib115","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.regpep.2006.07.007","article-title":"The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects","volume":"137","author":"Vilsb\u00f8ll","year":"2006","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2024.171214_bib116","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2036.2012.05198.x","article-title":"The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study","volume":"36","author":"Stevens","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.peptides.2024.171214_bib117","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.peptides.2024.171214_bib118","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.116.305665","article-title":"DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition","volume":"116","author":"Zhong","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.peptides.2024.171214_bib119","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/dme.12622","article-title":"Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide?","volume":"32","author":"Wu","year":"2015","journal-title":"Diabet. Med."},{"key":"10.1016\/j.peptides.2024.171214_bib120","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2146\/ajhp060564","article-title":"Vildagliptin: a novel oral therapy for type 2 diabetes mellitus","volume":"64","author":"Lauster","year":"2007","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.peptides.2024.171214_bib121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13300-013-0024-0","article-title":"Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies","volume":"4","author":"Engel","year":"2013","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.peptides.2024.171214_bib122","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib123","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2024.171214_bib124","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.peptides.2024.171214_bib125","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.peptides.2024.171214_bib126","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2024.171214_bib127","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2024.171214_bib128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2024.171214_bib129","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.peptides.2024.171214_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170174","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease","volume":"125","author":"Heimb\u00fcrger","year":"2020","journal-title":"Peptides"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978124000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978124000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:36:05Z","timestamp":1717115765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978124000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":130,"alternative-id":["S0196978124000676"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2024.171214","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of native glucose-dependent insulinotropic polypeptide in humans","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2024.171214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"171214"}}